The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Multiple myeloma accounts for approximately 10% of hematologic malignancies. The
diagnosis requires≥ 10% clonal bone marrow plasma cells or a biopsy proven …

Background Metformin is a commonly used drug for the treatment of diabetes. Accumulating
evidence suggests that it exerts anti-tumor effects in many cancers, including multiple …

Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their
impact should be measured against the expected outcome in patients failing current …

Objective To determine the clinical and laboratory features of newly diagnosed multiple
myeloma. Patients and Methods Records of all patients in whom multiple myeloma was …

Background The standard treatment for patients with multiple myeloma who are not
candidates for high-dose therapy is melphalan and prednisone. This phase 3 study …

Background High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We
studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior …

Background We conducted a randomized trial of the treatment of multiple myeloma with high-
dose chemotherapy followed by either one or two successive autologous stem-cell …

Most patients with newly diagnosed multiple myeloma (MM) are aged> 65 years with 30%
aged> 75 years. Many elderly patients are also vulnerable because of comorbidities that …

Background In multiple myeloma, combination chemotherapy with melphalan plus
prednisone is still regarded as the standard of care in elderly patients. We assessed whether …